Publications by authors named "Suzanne Chanel"

Claim this Profile
P
Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia.
Peter G Maslak, Tao Dao, Yvette Bernal, Suzanne M Chanel, Rong Zhang

Blood Adv· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hsp90 inhibition disrupts JAK-STAT signaling and leads to reductions in splenomegaly in patients with myeloproliferative neoplasms.
Gabriela S Hobbs, Amritha Varshini Hanasoge Somasundara, Maria Kleppe, Rivka Litvin, Maria Arcila, Suzanne Chanel

Haematologica· January 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumors.
Ellin Berman, Monica Girotra, Catherine Cheng, Suzanne Chanel, Robert Maki

Leuk Res· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia.
Todd L Rosenblat, Michael R McDevitt, Deborah A Mulford, Neeta Pandit-Taskar, Chaitanya R Divgi, Suzanne Chanel

Clin Cancer Res· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.
Peter G Maslak, Tao Dao, Lee M Krug, Suzanne Chanel, Tatyana Korontsvit

Blood· July 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Altered bone and mineral metabolism in patients receiving imatinib mesylate.
Ellin Berman, Maria Nicolaides, Robert G Maki, Martin Fleisher, Suzanne Chanel

N Engl J Med· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D3 analogue, in a phase I study of patients with advanced malignancies.
Robert Wieder, Steven C Novick, Bruce W Hollis, Margarette Bryan, Suzanne M Chanel

Invest New Drugs· November 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis